NEW YORK (GenomeWeb News) – MDS today reported that its third-quarter revenues fell 4 percent year over year and the firm swung to a loss from a profit on restructuring charges.
 
The Toronto-based firm brought in total revenues of $321 million for the three-month period ended July 31, compared to revenues of $333 million in the comparable period of 2007.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.